Literature DB >> 17646280

Interspecies prediction of human drug clearance based on scaling data from one or two animal species.

Huadong Tang1, Azher Hussain, Mauricio Leal, Michael Mayersohn, Eric Fluhler.   

Abstract

A data-driven approach was adopted to derive new one- and two-species-based methods for predicting human drug clearance (CL) using CL data from rat, dog, or monkey (n = 102). The new one-species methods were developed as CL(human)/kg = 0.152 x CL(rat)/kg, CL(human)/kg = 0.410 x CL(dog)/kg, and CL(human)/kg = 0.407 x CL(monkey)/kg, referred to as the rat, dog, and monkey methods, respectively. The coefficient of the monkey method (0.407) was similar to that of the monkey liver blood flow (LBF) method (0.467), whereas the coefficients of the rat method (0.152) and dog method (0.410) were considerably different from those of the LBF methods (rat, 0.247; dog, 0.700). The new rat and dog methods appeared to perform better than the corresponding LBF methods, whereas the monkey method and the monkey LBF method showed improved predictability compared with the rat and dog one-species-based methods and the allometrically based "rule of exponents" (ROE). The new two-species methods were developed as CL(human) = a(rat-dog) . W (human)(0.628) (referred to as rat-dog method) and CL(human) = a(rat-monkey) . W (human)(0.650) (referred to as rat-monkey method), where a(rat-dog) and a(rat-monkey) are the coefficients obtained allometrically from the corresponding two species. The predictive performance of the two-species methods was comparable with that of the three-species-based ROE. Twenty-six Wyeth compounds having data from mouse, rat, dog, monkey, and human were used to test these methods. The results showed that the rat, dog, monkey, rat-dog, and rat-monkey methods provided improved predictions for the majority of the compounds compared with those for the ROE, suggesting that the use of three or more species in an allometrically based approach may not be necessary for the prediction of human exposure.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17646280     DOI: 10.1124/dmd.107.016188

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  26 in total

Review 1.  Applications of human pharmacokinetic prediction in first-in-human dose estimation.

Authors:  Peng Zou; Yanke Yu; Nan Zheng; Yongsheng Yang; Hayley J Paholak; Lawrence X Yu; Duxin Sun
Journal:  AAPS J       Date:  2012-03-10       Impact factor: 4.009

2.  Practical anticipation of human efficacious doses and pharmacokinetics using in vitro and preclinical in vivo data.

Authors:  Tycho Heimbach; Suresh B Lakshminarayana; Wenyu Hu; Handan He
Journal:  AAPS J       Date:  2009-08-26       Impact factor: 4.009

3.  A single-species approach considering additional physiological information for prediction of hepatic clearance of glycoprotein derivate therapeutics.

Authors:  Patrick Poulin
Journal:  Clin Pharmacokinet       Date:  2011-10       Impact factor: 6.447

4.  Prediction of Metabolic Clearance for Low-Turnover Compounds Using Plated Hepatocytes with Enzyme Activity Correction.

Authors:  Bennett Ma; Roy Eisenhandler; Yuhsin Kuo; Paul Rearden; Ying Li; Peter J Manley; Sheri Smith; Karsten Menzel
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-04       Impact factor: 2.441

5.  Strategy for Extending Half-life in Drug Design and Its Significance.

Authors:  Hakan Gunaydin; Michael D Altman; J Michael Ellis; Peter Fuller; Scott A Johnson; Brian Lahue; Blair Lapointe
Journal:  ACS Med Chem Lett       Date:  2018-04-02       Impact factor: 4.345

6.  Structure-Activity Relationship of Novel and Selective Biaryl-Chroman GPR40 AgoPAMs.

Authors:  Helen Y Chen; Christopher W Plummer; Dong Xiao; Harry R Chobanian; Duane DeMong; Michael Miller; Maria E Trujillo; Melissa Kirkland; Daniel Kosinski; Joel Mane; Michele Pachanski; Boonlert Cheewatrakoolpong; Jerry Di Salvo; Brande Thomas-Fowlkes; Sarah Souza; Daniel A Tatosian; Qing Chen; Michael J Hafey; Robert Houle; Andrew F Nolting; Robert Orr; Juliann Ehrhart; Adam B Weinglass; Richard Tschirret-Guth; Andrew D Howard; Steven L Colletti
Journal:  ACS Med Chem Lett       Date:  2018-06-14       Impact factor: 4.345

7.  Physiologically Based Absorption Modeling to Design Extended-Release Clinical Products for an Ester Prodrug.

Authors:  Xuan Ding; Jeffrey S Day; David C Sperry
Journal:  AAPS J       Date:  2016-07-12       Impact factor: 4.009

8.  A novel in vitro allometric scaling methodology for aldehyde oxidase substrates to enable selection of appropriate species for traditional allometry.

Authors:  Rachel D Crouch; J Matthew Hutzler; J Scott Daniels
Journal:  Xenobiotica       Date:  2017-03-10       Impact factor: 1.908

9.  Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model.

Authors:  Chao Wu; Xi-Ling Jiang; Hong-Wu Shen; Ai-Ming Yu
Journal:  Biochem Pharmacol       Date:  2009-05-13       Impact factor: 5.858

10.  Preclinical pharmacokinetics of TPN729MA, a novel PDE5 inhibitor, and prediction of its human pharmacokinetics using a PBPK model.

Authors:  Zhi-wei Gao; Yun-ting Zhu; Ming-ming Yu; Bin Zan; Jia Liu; Yi-fan Zhang; Xiao-yan Chen; Xue-ning Li; Da-fang Zhong
Journal:  Acta Pharmacol Sin       Date:  2015-11-23       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.